This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
59
IV infusion over 30 minutes
IV infusion over 2 hours
Administered orally twice daily
Incidence of Adverse Events (Aes)
(non)
Time frame: From Day 1 up to 28 days after the end of the treatment phase
North America Clinical Trial Support Desk
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Administered orally twice daily
IV infusion over 30 minutes
Administered orally once daily for 5 days every 28 days
Chiba Clinical Site1
Kashiwa, Chiba, Japan
RECRUITINGEhime Clinical Site1
Matsuyama, Ehime, Japan
COMPLETEDFukuoka Clinical Site1
Kurume, Fukuoka, Japan
RECRUITINGHokkaido Clinical Site1
Sapporo, Hokkaido, Japan
RECRUITINGHyogo Clinical Site1
Akashi, Hyōgo, Japan
RECRUITINGKanagawa Clinical Site1
Yokohama, Kanagawa, Japan
RECRUITINGOita Clinical Site1
Yufu, Oita Prefecture, Japan
RECRUITINGOsaka Clinical Site1
Suita, Osaka, Japan
RECRUITINGOsaka Clinical Site3
Takatsuki, Osaka, Japan
RECRUITINGSaitama Clinical Site1
Hidaka, Saitama, Japan
RECRUITING...and 28 more locations